In any case, this news is a promising development for diabetes and obesity patients
The higher efficacy in weight reduction demonstrated in clinical trials in early, established or advanced TD2 versus placebo or active comparators [24] might influenced the choice of OW semaglutide in higher class of obesity
Formulation control matters because how tirzepatide is mixed, preserved, and delivered affects absorption
The decision between choosing Semaglutide or Tirzepatide ultimately depends on individual factors such as medical history, current medications, and personal preferences
Entry-dose compounded tirzepatide is the cheapest option, starting around $149 to $199/mo at the 2.5 mg starting dose from the lowest providers
Avoid stimulant laxatives (like senna or bisacodyl) for regular use, as these can create dependency